Testosterone Levels Link to U-Shaped Atrial Fibrillation Risk

High testosterone levels may carry a previously underappreciated cardiovascular risk, according to a recent analysis of available studies. Researchers examining the connection between male hormones and atrial fibrillation note that the danger forms a U-shaped curve, where both abnormally low and excessively high levels of the hormone correspond to an increased incidence of irregular heartbeats.

Atrial Fibrillation Risks at Both Hormone Extremes

Medical literature has traditionally focused on the dangers of deficient testosterone, frequently associating reduced hormone output with cardiovascular complications. Data from a large study involving over 76 mila veterani americani showed that male patients with initially low testosterone who underwent therapy to restore normal levels experienced fewer episodes of atrial fibrillation.

However, subsequent evaluations have complicated that established view by highlighting the opposite end of the spectrum. An analysis of over 4,500 older men demonstrated that individuals with the highest testosterone concentrations faced nearly double the risk of atrial fibrillation compared to peers in intermediate ranges. Additional findings from the TRAVERSE study, which evaluated more than 5 mila uomini tra i 45 e gli 80 anni, recorded atrial fibrillation in 3.5 percent of participants treated with testosterone gel, contrasted with 2.4 percent in the placebo group. An analysis over 4,500 older men observed that subjects with the highest testosterone values presented almost double the risk of atrial fibrillation compared to those placed in the intermediate bracket.

Testosterone Levels Influence Heart Cell Electrical Processes

Researchers are currently investigating the cellular processes behind these observations. Insufficient testosterone may disrupt the calcium regulation inside heart cells, whereas excessively high amounts can alter potassium flows that govern how cardiac tissue recovers after an electrical impulse.

Isolating the direct impact of the hormone remains challenging because low testosterone frequently correlates with advanced age, obesity, and other underlying health conditions that independently raise arrhythmia risks. A broader review of more than 100 trials and over 15 million participants did not establish a definitive, universal increase in risk from replacement therapy. It is for this reason that today nobody can simply say that testosterone therapy fa male al cuore.

Current data indicate that a hormone range between 350 and 550 nanograms per deciliter corresponds to the lowest observed arrhythmia risk in existing studies. Researchers emphasize that this bracket is not a definitive clinical threshold or a rigid rule designed to guarantee protection.

Patients pursuing hormone therapy are advised to focus on achieving a suitable personal level under medical supervision rather than chasing maximum numbers. Proper management requires monitoring age, body weight, blood pressure, and pre-existing cardiovascular conditions rather than treating hormone levels as a competitive target.